European Drug Regulator Recommends Against Approving Zevra Therapeutics' Drug for Neurodegenerative Disorder

Dow Jones11-13
 

European drug regulators have recommended against approving Zevra Therapeutics' drug arimoclomol for the treatment of Niemann-Pick disease type C (NPC), a rare neurodegenerative disorder.

Zevra said Friday that the European Commission is expected to issue its final decision on the marketing authorization application for the drug within 67 days.

The negative opinion on the application came from the European Medicines Agency's Committee for Medicinal Products for Human Use, which is responsible for assessing the quality, safety and efficacy of medicines, and recommending whether the European Commission should approve them.

Zevra said it believes the data it provided for arimoclomol, including from a Phase 2/3 trial, supports its therapeutic benefit in NPC.

The company said it will continue to support eligible patients currently receiving arimoclomol through its global expanded access program, and that it will continue to advance scientific understanding of NPC.

"We are deeply disappointed by the CHMP's opinion, particularly given the significant unmet medical need faced by individuals and families living with NPC," Chief Executive Neil McFarlane said.

NPC affects about 1,000 people in Europe.

Zevra's stock slid 6.0% to $10.49 in premarket trading Friday.

 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment